News

This new data adds to the growing body of literature regarding the benefits and risks of prescribing isotretinoin for dermatology patients.

At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.

Metformin use was associated with a reduced likelihood of any AMD and dry AMD in a sample of patients without diabetes.

In this interview with Dr. Eichenfield, comparisons between ruxolitinib and other treatments for eczema were discussed.

Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

This discussion with Dr. Eichenfield featured coverage of data on ruxolitinib for eczema patients.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

Ophthalmology registry data show increased macular fluid volume after initial treatment are associated with increased numbers of injections in nAMD treatment.

Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.

Factors associated with receiving eye care in past 12 months included a higher educational level and income, while food and housing insecurity were associated with not receiving eye care.

A trial randomizing brain-dead donor hearts to levothyroxine administration or saline has returned results challenging conventional wisdom on the topic, with data indicating thyroid hormone administration may provide no significant benefit.

Patients with juvenile onset fibromyalgia and joint hypermobility demonstrated poorer overall functioning compared with those without joint hypermobility.

A qualitative study in Denmark explores the adherence of patients with nAMD to their treatment regimen despite various barriers, including access to care and poor health literacy.

This data may bring patients with the rare immunobullous disease closer to an eventual FDA-approved treatment.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

Data from a phase 3 trial of CT-P43 in patients with moderate to severe plaque psoriasis offers additional insight into the comparative effects of the biosimilar relative to ustekinumab.

The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.

An analysis of data from the Veterans Health Administration provides insight into disparities in the rates of endoscopy or colonoscopy among patients with iron deficiency anemia or hematochezia.

The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.

These new findings show promise for patient-reported outcomes, though additional research may be warranted to assess other measurement properties of the DermSat-7.

A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.

Nationwide data from Korea suggest abstinence from alcohol led to lower risks of clinical outcomes among patients with newly diagnosed open-angle glaucoma.

During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.

Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.

Results of the COMPACT study detail persistence rates, QoL data, and efficacy of biosimilar etanercept among patients in real-world settings.

The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.

Data from a 24-week, prospective trial conducted at a hospital in China provide insight into the effects of roxadustat on iron metabolism relative to use of ESAs in patients using peritoneal dialysis.

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.